Subcutaneous immunoglobulin is an effective and well-tolerated alternative to intravenous immunoglobulin for myasthenia gravis.
American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM)
Shorts
0:46
Improving Future CIDP Trial Design
a month ago
by
Marco Meglio(+1 more)
1:16
Primary Phase 2 Results for CAR T-Cell Therapy in gMG
a month ago
by
Marco Meglio(+1 more)
1:13
Emerging Therapies in Neuromuscular Disorders
10 months ago
by
Amit Sachdev, MD, MS(+1 more)
1:08
Integrating AI and Translational Science to Advance ALS Care
10 months ago
by
Crystal Yeo, MD, PhD(+1 more)
1:15
Evolving Landscape of Myasthenia Gravis Treatment
a year ago
by
Leila Darki, MD(+1 more)
Latest Content
Eculizumab showed sustained activity and tolerability through 3 years for generalized myasthenia gravis.
Advertisement
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
Myelin Repair Research in MS: Lessons From Clinical Trials and the Road Ahead
3
FDA Requires NAION Warning Across GLP-1 Receptor Agonist Class
4
From Glucose to Cognition: Where Repurposed Diabetes Drugs Stand in Alzheimer Disease
5